Company Encyclopedia
View More
name
Orthofix
OFIX.US
Orthofix Medical Inc. operates as a medical technology company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulation devices that enhance bone fusion, including adjunctive and noninvasive treatment of the cervical and lumbar spine, as well as a therapeutic treatment for non-spinal, appendicular fractures, and fresh fractures that have not healed; designs, develops, and markets a portfolio of spine fixation and motion preservation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal, orthopedic, and dental conditions.
1.407 T
OFIX.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking66/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-24.60%E
    • Profit Margin-14.56%D
    • Gross Margin72.23%A
  • Growth ScoreC
    • Revenue YoY4.31%C
    • Net Profit YoY-0.08%C
    • Total Assets YoY-4.06%D
    • Net Assets YoY-15.87%E
  • Cash ScoreD
    • Cash Flow Margin-686.77%E
    • OCF YoY4.31%C
  • Operating ScoreA
    • Turnover0.96A
  • Debt ScoreC
    • Gearing Ratio46.86%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Orthofix International Reports Strong Q3 Earnings Growth

    Orthofix International reported strong Q3 earnings with a 6% year-over-year increase in global net sales, reaching $203.4 million. The U.S. Spine and Orthopedics segments drove this growth, with the Orthopedics segment achieving a remarkable 19% increase. The company generated positive free cash flow of $2.5 million and expanded its EBITDA margins for the seventh consecutive quarter. Despite challenges like pricing pressure and product discontinuation, Orthofix narrowed its full-year sales guidance to $810-$814 million, indicating a positive outlook for future growth.

    Tip Ranks·
    US
    OFIX
    -0.13%
    Tip Ranks·
    US
    OFIX
    -0.13%

    Orthofix | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 205.63 M

    LB filings·
    US
    OFIX
    -0.13%
    LB filings·
    US
    OFIX
    -0.13%

    Orthofix Medical Inc. SEC 10-Q Report

    Orthofix Medical Inc. has released its Form 10-Q report for Q3 2025, showing financial improvements with net sales of $205.6 million, a 4.6% increase from Q3 2024. Gross profit rose to $148.5 million, reflecting a 10% increase. The operating loss improved to $(17.0) million, and net loss decreased to $(22.8) million. Key growth drivers included Bone Growth Therapies and Spinal Implants, with significant contributions from the U.S. market. The company expects continued growth in core product lines and plans to focus on profitable opportunities after discontinuing the M6 product lines.

    TradingView·
    US
    OFIX
    -0.13%
    TradingView·
    US
    OFIX
    -0.13%

    Orthofix beats Q3 sales estimates, narrows FY forecast

    Orthofix reported Q3 net sales of $205.6 million, a 5% year-over-year increase, surpassing analyst expectations. Adjusted EBITDA rose 28.2% year-over-year. The company narrowed its full-year net sales guidance to $810-$814 million and raised the low end of adjusted EBITDA guidance to $84-$86 million. U.S. Spine Fixation sales grew 8%, and Orthopedics sales increased by 19%. Analysts maintain a "buy" rating, with a median 12-month price target of $23.00, reflecting a potential 30.2% upside from the recent closing price of $16.06.

    Reuters·
    US
    OFIX
    -0.13%
    Reuters·
    US
    OFIX
    -0.13%

    Orthofix | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 205.63 M

    LB filings·
    US
    OFIX
    -0.13%
    LB filings·
    US
    OFIX
    -0.13%
    © 2025 Longbridge｜Disclaimer